Related Experiment Videos
Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype
E Berman1, M Adams, R Duigou-Osterndorf
1Laboratory of Hematopoietic Cell Kinetics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
Abstract:
We examined the effect of tamoxifen (Tmx), verapamil, and daunorubicin (DNR) in two cell lines that displayed the multidrug-resistant (MDR) phenotype and used laser flow cytometry to quantitate intracellular DNR content. In the vinblastine-resistant human lymphoblastic lymphoma cell line CEM-VBL, simultaneous incubation of DNR with Tmx 10 mumol/L or Tmx 50 mumol/L increased intracellular DNR fluorescence in a dose-dependent manner and demonstrated an uptake pattern similar to that seen with DNR and verapamil. Similar results were obtained in the vincristine-resistant human myeloid leukemia cell line HL-60/RV+. Cellular retention of DNR was also measured in both cell lines and results suggested that continuous exposure of the cells to Tmx resulted in higher intracellular DNR content compared with cells resuspended in fresh medium. No effect of Tmx or verapamil was observed in the drug-sensitive parent cell lines CEM or HL-60. Clonogenic experiments were then performed to determine whether Tmx was itself inhibitory to cell growth or whether Tmx potentiated DNR cytotoxicity. Tmx 10 mumol/L did not significantly inhibit either CEM-VBL or HL-60/RV+ cells after a 3-hour exposure followed by culture in methylcellulose. Tmx 50 mumol/L was significantly more inhibitory in both cell lines. However, cells that had been incubated with DNR and Tmx 10 mumol/L demonstrated a marked increment in growth inhibition compared with cells that had been incubated with DNR alone or Tmx 10 mumol/L alone. Based on the data presented here, we suggest that clinical testing of Tmx and DNR be pursued in the setting where MDR may play a role.
Insights
Tamoxifen (Tmx) increases intracellular daunorubicin (DNR) uptake and retention in multidrug-resistant (MDR) cancer cells. Tmx enhances DNR
Area of Science:
- Pharmacology
- Cancer Biology
- Drug Resistance
Background:
- Multidrug resistance (MDR) is a major challenge in cancer chemotherapy.
- Tamoxifen (Tmx) and verapamil are known modulators of drug efflux pumps.
- Daunorubicin (DNR) is an anthracycline chemotherapy drug.
Purpose of the Study:
- To investigate the effect of tamoxifen (Tmx) and verapamil on intracellular daunorubicin (DNR) content in multidrug-resistant (MDR) cell lines.
- To evaluate the impact of Tmx on DNR cytotoxicity and cellular retention in MDR cells.
- To determine if Tmx potentiates DNR's anti-cancer effects.
Main Methods:
- Utilized laser flow cytometry to quantify intracellular DNR fluorescence in MDR cell lines (CEM-VBL and HL-60/RV+).
- Assessed cellular retention of DNR with continuous Tmx exposure.
- Performed clonogenic assays to evaluate Tmx's inherent cytotoxicity and its potentiation of DNR cytotoxicity.
Main Results:
- Tmx significantly increased intracellular DNR uptake and retention in a dose-dependent manner in MDR cell lines, similar to verapamil.
- Continuous Tmx exposure led to higher intracellular DNR levels compared to fresh medium.
- Tmx alone at 10 µmol/L showed minimal inhibition, but potentiated DNR cytotoxicity significantly.
Conclusions:
- Tamoxifen effectively enhances intracellular daunorubicin accumulation in multidrug-resistant cancer cells.
- Tamoxifen potentiates the cytotoxic effects of daunorubicin, suggesting a potential therapeutic synergy.
- Clinical investigation of tamoxifen and daunorubicin combination therapy is warranted for MDR cancers.